Insomnia disorder

Area of Science:

• Sleep Medicine
• Neuroscience
• Psychiatry

Background:

• Insomnia disorder (ID) presents with nighttime sleep difficulties and daytime impairments like fatigue and cognitive deficits.
• ID affects 10-16% of adults, imposing a significant burden and acting as a risk factor for other health conditions.
• Current diagnosis relies on self-report, lacking a definitive biomarker, highlighting the need for improved diagnostic and therapeutic strategies.

Purpose of the Study:

• To review the current understanding of insomnia disorder (ID) pathophysiology and treatment.
• To emphasize the need for improved accessibility and implementation of cognitive behavioral therapy for insomnia (CBT-I).
• To underscore the necessity for developing novel interventions for ID.

Main Methods:

• Literature review of etiological and pathophysiological research in ID.
• Analysis of current clinical guidelines and treatment recommendations for ID.
• Evaluation of the efficacy and limitations of existing pharmacological and behavioral treatments for ID.

Main Results:

• ID is characterized by complex symptoms and significant public health impact.
• Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, with digital CBT-I offering scalability.
• Pharmacological treatments for ID are often limited to short-term use due to efficacy and safety concerns.

Conclusions:

• Further research and development of novel interventions are crucial for effective ID management.
• Widespread implementation of CBT-I, including digital formats, is essential to improve treatment accessibility.
• Addressing the unmet needs in ID treatment requires a multi-faceted approach, combining refined existing therapies and innovative solutions.